Clinical trial NCT00663416: REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
Official title: A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Stroke
Lead sponsor: Stem Cell Therapeutics Corp.
Sponsor class: INDUSTRY
First posted: 2008-04-22
Enrollment: 134
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary objective: To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a placebo control.

Secondary objective: To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke patients.


Eligibility criteria: Inclusion Criteria:

* Age 18-85.
* NIHSS score 6-24 within 24-48 hours after stroke onset and enrolment.
* Stroke is ischemic in origin, supratentorial, and radiologically confirmed (CT scan or diagnostic MRI) prior to enrolment.
* Patient is 24-48 hours from time of stroke onset when the first dose of NTxTM-265 therapy is administered. Time of onset is when symptoms began; for stroke that occurred during sleep, time of onset is when patient was last seen or was self-reported to be normal.
* Reasonable expectation of availability to receive the full 9 day NTxTM-265 course of therapy, and to be available for subsequent follow-up visits.
* Reasonable expectation that patient will receive standard post-stroke physical, occupational and speech therapy as indicated.
* Female patient is either:

  1. Not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral oophorectomy or hysterectomy) or
  2. If of childbearing potential, agrees to use two of the following effective separate forms of contraception throughout the study, up to and including the follow-up visits:

     * Condoms, sponge, foams, jellies, diaphragm or intrauterine device, contraceptives (e.g., implants, injectables, combined oral, etc) OR
     * A vasectomised partner OR
     * Abstinence

Exclusion Criteria

* Patients presenting with lacunar, hemorrhagic and/or brain stem stroke.
* Patients who have received thrombolytic treatment with tPA following the index stroke.
* Patients classified as comatose, defined as a patient who required repeated stimulation to attend, or is obtunded and requires strong or painful stimulation to make movements (NIHSS 1A score must be \<2)
* Women who have tested positive for pregnancy, or are breast-feeding or are not using a highly effective method of birth control that can be maintained for the duration of the study.
* Serum hemoglobin \> 16 g/dL (males) or \> 14 g/dL (females); or platelet count \> 400,000/mm3.
* Advanced liver,kidney, cardiac or pulmonary disease; the former will be operationally defined using NCI Toxicity Criteria (Grade 2 or higher)
* Serum bilirubin \> 1.5 x upper limit of normal (ULN).
* Alkaline phosphatase \> 2.5 x ULN.
* AST\>2.5xULN.
* ALT \> 2.5 x ULN.
* Creatinine \> 2.0 x ULN.
* Patients with known and documented transferrin saturation \< 20%.
* Patients with known and documented ferritin \< 100 ng/mL.
* Patients with known and documented elevated PSA levels, or a PSA level of ≥ 4 ng/mL at screening.
* Patients with a known or current history of abnormal hypercoagulability parameters , including known cardiolipin/antiphospholipid antibody syndrome.
* Expected survival \< 1 year.
* Allergy or other contraindication to hCG including:

  1. Prior hypersensitivity to hCG preparations or one of their excipients.
  2. Primary ovarian failure.
  3. Uncontrolled thyroid or adrenal dysfunction.
  4. An uncontrolled organic intracranial lesion such as a pituitary tumor.
  5. Abnormal uterine bleeding of undetermined origin.
  6. Ovarian cyst or ovarian enlargement of undetermined origin.
  7. Sex hormone dependent tumors of the reproductive organs, accessory sex glands, and breasts.
* Allergy or other contraindication to epoetin alfa:

  1. Who developed pure red cell aplasia following treatment with any erythropoiesis regulating hormones
  2. With uncontrolled hypertension
  3. With known hypersensitivity to mammalian cell-derived products, albumin (human) or any component of the product
  4. Who for any reason cannot receive adequate antithrombotic treatment
* A known diagnosis of cancer (except non-malignant skin cancer).
* Uncontrolled hypertension, defined in the context of acute stroke as blood pressure persistently above 220 mm Hg systolic or 120 mm Hg diastolic despite antihypertensive therapy.
* Use of either hCG or epoetin alfa within the previous 90 days.
* Any condition known to elevate hCG, active in the prior 24 months, e.g., choriocarcinoma or germ cell tumor.
* Patients with a pre-stroke/pre-morbid modified Rankin Score (mRS) ≥ 2.
* Any patients living in a nursing home or supervised living center. Patients must be historically fully independent in all activities of daily living including banking, shopping, cooking, toileting, showering and dressing.
* Any other medical condition or degree of stroke such that, in the investigator's opinion, the patient should not be included in the trial.
* With the exception of the qualifying stroke, any other stroke within the previous 6 months.
* Patients who cannot take anti-platelet therapy for the duration of the study.
* Patients who cannot take low molecular weight or unfractionated heparin during hospitalization.
* Pre-existing and active major psychiatric or other chronic neurological disease.
* Consume, on average, greater than 14 alcoholic drinks per week, or have a history of substance abuse or dependency within 12 months prior to the study.
* Currently participating in another investigational study.

Primary outcomes:
measure: Modified Rankin Score (mRS)
timeFrame: Day 90
measure: NIHSS response
timeFrame: Day 90
Secondary outcomes:
measure: NIHSS
timeFrame: Day 90
measure: mRS
timeFrame: Day 90
measure: Barthel Index
timeFrame: Day 90
measure: Action Research Arm Test
timeFrame: Day 90
measure: Gait Velocity Test
timeFrame: Day 90
measure: Boston Naming Test
timeFrame: Day 90
measure: Line Cancellation Test
timeFrame: Day 90
measure: Trails A & B Test
timeFrame: Day 90
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: Department of Clinical Neurosciences, Univeristy of Calgary
state: Alberta
city: Edmonton
country: Canada
facility: Walter Mackenzie Health Sciences Centre
state: Alberta
city: Edmonton
country: Canada
facility: Grey Nuns Community Hospital
state: Alberta
city: Lethbridge
country: Canada
facility: Chinook Regional Hospital
state: Alberta
city: Penticton
country: Canada
facility: Penticton Regional Hospital
state: British Columbia
city: Vancouver
country: Canada
facility: Vancouver General Hospital
state: British Columbia
city: Victoria
country: Canada
facility: Vancouver Island Health Research Centre
state: British Columbia
city: Brandon
country: Canada
facility: Brandon Regional Health Centre
state: Manitoba
city: Halifax
country: Canada
facility: Queen Elizabeth II Health Sciences Centre
state: Nova Scotia
city: Hamilton
country: Canada
facility: McMaster Clinic
state: Ontario
city: Mississauga
country: Canada
facility: Trillium Health Centre
state: Ontario
city: Thunder Bay
country: Canada
facility: Thunder Bay Regional Health Sciences Centre
state: Ontario
city: Toronto
country: Canada
facility: Division of Neurology , Sunnybrook Health Sciences Centre
state: Ontario
city: Toronto
country: Canada
facility: Department of Neurology, St. Michael's Hospital
state: Ontario
city: Toronto
country: Canada
facility: University Health Network
state: Ontario
city: Montreal
country: Canada
facility: Montreal Neurological Institute
state: Quebec
city: Hyderabad
country: India
facility: Department of Neurology, Care Hospital
state: Andhra Pradesh
city: Hyderabad
country: India
facility: Krishna Institute of Medical Sciences
state: Andhra Pradesh
city: Hyderabad
country: India
facility: Department of Neurology, Apollo Hospitals
state: Andhra Pradesh
city: Hyderabad
country: India
facility: Department of Neurology, Nizam's Institute of Medical Science
state: Andhra Pradesh
city: New Delhi
country: India
facility: Max Super Speciality Hospital
state: Delhi
city: Bangalore
country: India
facility: M S Ramaiah Memorial Hospital
state: Karnataka
city: Ludhiana
country: India
facility: Christian Medical College & Hospital
state: Punjab
city: Vellore
country: India
facility: Department of Neurology, Christian Medical College
state: Tamilnadu
city: Kolkata
country: India
facility: AMRI Hospital
state: West Bengal
city: Kolkata
country: India
facility: Department of Neurology, B.P.Poddar Hospital & Medical Research Ltd
state: West Bengal
Study officials:
affiliation: Department of Clinical Neurosciences, University of Calgary
name: Michael D Hill, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Neurology, University of Califonia, Irvine Medical Center
name: Steven C Cramer, MD
role: PRINCIPAL_INVESTIGATOR
References: